Recent News About Abbvie View More

Judge: Settlement talks begun in mass action vs Abbvie, others over Androgel, testosterone drugs

By Jonathan Bilyk | Sep 10, 2018

A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.

Lawsuit: Abbvie's after-hours share offer adjustment cost investors $100M

By Scott Holland | Jul 30, 2018

A group of Abbvie investors who say they and others like them collectively lost more than $100 million when the pharmaceutical giant used an after-hours press release to adjust a share price tender offer, has sued the company in a federal securities class action filed July 26 in Chicago.

Judge orders new trial, tosses $140M verdict vs AbbVie over Androgel testosterone drug

By Jonathan Bilyk | Jul 5, 2018

A federal judge has knocked down a $140 million verdict against pharmaceutical maker AbbVie, ordering a new trial over a man’s claims AbbVie’s Androgel testosterone replacement therapy drug caused him to suffer a heart attack.

The Record Network